Biofrontera (NASDAQ:BFRI) Shares Up 1.6% – Should You Buy?

Shares of Biofrontera Inc. (NASDAQ:BFRI) shot up 1.6% on Thursday . The stock traded as high as $0.90 and last traded at $0.86. 30,131 shares traded hands during trading, a decline of 92% from the average session volume of 374,771 shares. The stock had previously closed at $0.85.

Biofrontera Stock Up 1.6%

The company has a debt-to-equity ratio of 8.99, a current ratio of 0.96 and a quick ratio of 0.75. The company has a market capitalization of $8.76 million, a price-to-earnings ratio of -0.38 and a beta of 0.49. The firm has a 50-day moving average price of $0.92 and a two-hundred day moving average price of $0.81.

Biofrontera (NASDAQ:BFRI) last issued its quarterly earnings results on Wednesday, August 13th. The company reported ($0.57) EPS for the quarter, missing the consensus estimate of ($0.45) by ($0.12). Biofrontera had a negative net margin of 42.34% and a negative return on equity of 1,104.09%. The company had revenue of $9.03 million for the quarter, compared to analyst estimates of $8.30 million. As a group, sell-side analysts anticipate that Biofrontera Inc. will post -3.01 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

An institutional investor recently raised its position in Biofrontera stock. Rosalind Advisors Inc. boosted its stake in shares of Biofrontera Inc. (NASDAQ:BFRI) by 51.5% in the 2nd quarter, according to its most recent Form 13F filing with the SEC. The fund owned 976,448 shares of the company’s stock after purchasing an additional 332,055 shares during the period. Biofrontera accounts for about 0.3% of Rosalind Advisors Inc.’s investment portfolio, making the stock its 27th biggest holding. Rosalind Advisors Inc. owned 9.63% of Biofrontera worth $695,000 as of its most recent filing with the SEC. Hedge funds and other institutional investors own 10.08% of the company’s stock.

Biofrontera Company Profile

Biofrontera Inc, a biopharmaceutical company, engages in the commercialization of pharmaceutical products for the treatment of dermatological conditions in the United States. The company's products are used for the treatment of actinic keratoses, which are pre-cancerous skin lesions, as well as impetigo, a bacterial skin infection.